Flu is an ever-evolving virus, which means vaccines and vaccine management programmes must evolve too. CSL Seqirus’ latest innovation, flu360, can help practice managers to manage their CSL Seqirus vaccines more effectively and efficiently than ever
This is a sponsored article brought to you by CSL Seqirus.
flu360.co.uk is for GB healthcare professionals only.
Globally, the World Health Organization estimates that the flu kills 290,000 to 650,000 people per year1, but the number would be much larger without flu vaccine suppliers such as CSL Seqirus, which has been a leader in the fight against influenza for more than a century – and is still at the forefront now.
From the very start in 1916, CSL has been focused on protecting people’s health, responding to the Spanish Flu pandemic in 1919 by providing 3 million doses of a mixed bacterial vaccine to protect Australian citizens. In 1944, CSL started production of a flu vaccine, protecting the troops in the Second World War. Ever since, CSL Seqirus has been on the front line in the fight against flu and in that time, millions of people have benefitted from CSL Seqirus flu vaccines. Today, the company remains a global leader in the field of influenza protection and seeks to remain one step ahead of flu, every step of the way.
Staying one step ahead
Remaining one step ahead of flu requires constant innovation, as viral strains never stop evolving. While CSL Seqirus have been providing influenza vaccine support for more than 100 years, protecting people from what can be a deadly virus, building on their experience – they constantly seek to advance their understanding of flu and develop ever more effective vaccines. By using the latest scientific and technical capabilities and research, CSL Seqirus work with a range of partners to protect communities around the world from seasonal flu and global pandemic threats.
However, the fight against flu relies on more than vaccination alone, but also how vaccination programmes are delivered and the administration behind them.
At practice level we are seeing the growth of dynamic online portals, driven by evolving needs and expectations. For instance, in a recent survey, 87% of CSL Seqirus customers said they had already used online portals to order supplies for their practice. Just as significantly, 96% said they were satisfied or very satisfied with their experience of using those portals, with convenience, ease, flexibility and speed being the main benefits.
Introducing flu360.co.uk
These evolving needs led CSL Seqirus to develop flu360, their latest offering to support the smooth running of the flu vaccine programme with a wide range of applications for pre-season, in-season and post-season flu management.
flu360 offers so much more than just supplying flu vaccines to healthcare providers; CSL Seqirus supports vaccinators in the delivery of their respective flu programmes in the best possible way to help protect communities from the annual flu strains.
With flu360, CSL Seqirus moves beyond being a flu partner, and offers a flu platform, with the aim of simplifying flu vaccine management. For instance, on flu360, you can access all the information needed to run a flu vaccination programme with CSL Seqirus vaccines in one place, making management easier and saving valuable time. At CSL Seqirus, they understand time demands on HCPs and how reducing administration frees up vital time.
“flu360 was purpose-built around the priorities of our customers, aligned to our central mission of helping to simplify the ordering and delivery of CSL Seqirus flu vaccines” says Brogan Lear, CSL Seqirus’ Digital Experience Lead. “We continually look to learn from our customers and address their evolving needs, by enhancing the user experience through ongoing updates to the site.”
The flu360 build team add that: “by employing an extensive strategy, user experience, and design process, we’ve created a digital experience that is both familiar and innovative to the customer, allowing them to find information easily and to perform tasks confidently and efficiently.”
All around benefits
Some of the other benefits of using flu360 include increased operational efficiency, as users can place, review and amend orders, manage invoicing and initiate and monitor their returns. They can also view their upcoming deliveries, update their account information and share access with multiple users.
In addition, there is a wealth of flu programme support materials that can be accessed on flu360 that can help programme managers, particularly in setting up their flu clinics. For instance, in the flu360 Material Hub, providers can learn more about the vaccines that have been ordered – including their clinical effectiveness and safety profile, as well as request disease awareness and clinic support materials. They can also access the flu360 Knowledge Hub to keep up to date with the latest news on flu including exclusive medical education materials.
Initial feedback from flu360 customers has been very positive and CSL Seqirus’ Customer Service team are already hearing great things about it, including how efficient it is to have everything in one place, which helps customers coordinate and plan their flu campaigns.
“At CSL Seqirus, we recognise that our customers are under increasing pressure, juggling competing priorities to serve their patients and communities,” adds Louise Schlienger, Brand Manager at CSL Seqirus. “While our existing customer service channels remain open as ever during business hours, flu360 allows our customers to self-serve on their own schedule. The platform consolidates key communications and updates in one location, and offers supplementary educational and clinic support resources, giving our customers easy access to additional support.”
flu360 is a new way to manage key aspects of your flu programme, whether that’s ordering, coordinating, educating or providing support, flu360 will help you to deliver your vaccination programme more efficiently.
For more information and to register go to flu360.co.uk and start enjoying the benefits.
This is a sponsored article, brought to you by CSL Seqirus.
To find out more about CSL Seqirus, you can contact their Customer Service Team, available 08.00-17.00 on business days. Call: 0845 745 1500 Email: [email protected]
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events relating to CSL Seqirus products should also be reported to Seqirus UK Limited on 01748 828816.
1. Seqirus Data on File, August 2023. SREF–17994. 2. Adjuvanted Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics. 3. Cell-based Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics.
Be the first to comment